



an Open Access Journal by MDPI

Antibiotics Research in Canada

Guest Editors:

Prof. Dr. Raymond J. Turner

Department of Biological
Sciences, University of Calgary,
Calgary, AB T2N 1N4, Canada

Prof. Dr. Roger C Levesque

Microbiologie Médecine FRQS
Chercheur Boursier Mérite
Exceptionnel, Institut de Biologie
Intégrative et des Systèmes
(IBIS), Université Laval, Québec,
QC G1K 7P4, Canada

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

We would like to invite you to contribute a manuscript to a Special Issue focusing on Canadian Research efforts in the area of Antibiotics. As Canadian researchers, we are part of a strong history of contributions to the field of novel antibiotic developments and studying the resistance/tolerance/sensitivity processes. Canadian research in this area is broad, ranging from an academic interest in fundamental microbiology to the development of novel antimicrobials and bench-to-bed clinical research. With the understanding of antibiotic misuse in medicine and various industries, we all recognize that we are entering the post-antibiotic era and are well within the AMR era. The Antimicrobial Resistance initiative from the Canadian Institutes of Health Research within the Infection and Immunity Institute, international Joint initiatives, and our National Laboratory have provided many Canadian scientists with the ability to conduct novel and internationally competitive work. Recent cross-Canada projects considering a One Health approach to prevent or reduce the development and transmission of AMR are helping direct public outreach education and policies.



mdpi.com/si/67238

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi